For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies…
Dianthus
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards…
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD)…
Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make…
Follow these 7 tips when pipetting small volumes to get consistent assay results
If you’ve ever had to pipette really small volumes, such as what is required in…
6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the…
3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs
A caveat to a successful pharmaceutical industry in which many effective drugs have already been…
The NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper…
3 big takeaways from SLAS on the future of automation and screening
5,200 researchers, representing all of life sciences, gathered in San Diego in late January to…